On August 18, Liquidia Technologies Inc fell 5.1% in regular trading, trading at approximately $74.0 per share with turnover of $20.15 million, extending the pullback trend following its Q2 earnings release.

On August 12, the company reported Q2 earnings per share of $0.74, missing the FactSet consensus estimate of $0.76, while revenue of $171.7 million significantly exceeded the expected $168.5 million, surging from $8.8 million in the year-ago period. Core product YUTREPIA recorded net sales of approximately $170.4 million, up 31% sequentially, with approximately 5,900 unique patient prescriptions.

Despite strong top-line momentum reflecting rapid commercial adoption of YUTREPIA, the slight EPS miss has triggered sustained profit-taking given the stock had already more than doubled year-to-date. Additionally, BofA Securities had previously downgraded the stock to Neutral from Buy with a $79 price target in late June, reflecting a view that much of the upside had already been priced in.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)